Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAROCCO study
2016-003964-38Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cediranib, olaparib and paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Progression-free survival. Started May 2021; status: completed.
02
Drugs
cediranibolaparibpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2016-003964-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003964-38.